Susan M. O’Brien, MD, discusses the challenges with the 3 oral agents approved in chronic lymphocytic leukemia.
Susan M. O’Brien, MD, associate director for clinical sciences, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, discusses the challenges with the 3 oral agents approved in chronic lymphocytic leukemia (CLL).
Ibrutinib (Imbruvica) is the only agent approved in the frontline setting currently, but venetoclax (Venclexta) is now being investigated in a randomized clinical trial with obinutuzumab (Gazyva), another novel anti-CD20 monoclonal antibody, O’Brien says. Based on that data, there may be more options for the frontline treatment of CLL, but it would make sequencing more complicated.
Novel Approaches Focus on Limiting Toxicity in Older Patients With ALL
April 22nd 2024The major challenges for clinicians treating older patients with acute lymphoblastic leukemia surround the emergence of resistance to existing therapies and the toxicities associated with current chemotherapies.
Read More